Commercialization named as remaining task

The claim centers on whether the project can safeguard its three-year performance, with commercialization after the project's end highlighted as a decisive factor. The business team itself has explicitly listed commercialization after the project concludes as a remaining task, and no evidence has emerged to contradict that framing.

The project's official website presents K-MELLODDY as a collaborative AI drug development initiative, with materials outlining its goals and organization.

Outlook

Whether the consortium can convert its research outcomes into commercial results within its project period remains unconfirmed. The question of how the three-year achievements are protected and carried forward stands as the central point of contention raised in the claim.

On balance, the claim holds up: the commercialization challenge is consistent with what the project team itself has stated, leaving the assertion largely accurate. Verdict: Mostly True